Content area

|
|

Malignt pleuralt mesoteliom

Forfatter(e)
Sajitha Sophia Sritharan1, 2, Jens Lundby Frandsen2, Øyvind Omland3 & Jens Meldgaard Bruun2 1) Lungemedicinsk Afdeling, Aarhus Universitetshospital 2) Medicinsk Afdeling, Regionshospitalet Randers 3) Det Sundhedsvidenskabelige Fakultet, Klinisk Institut, Arbejdsmedicin, Aalborg Universitetshospital Ugeskr Læger 2018;180:V06170439
Reference: 
Ugeskr Læger 2018;180:V06170439
Sidetal: 
2-6
Malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. The disease is of importance, since the incidence in Denmark is increasing despite cessation of the use of asbestos in the 1980s. MPM has a long latency period, and the first symptom is often dyspnoea, typically caused by pleural effusion. The diagnosis is a challenge, because cytology often is non-conclusive, and thoracoscopy is needed to obtain biopsies for immunohistochemistry. The occupational history is important, since the patients are entitled to compensation. The treatment is often limited to palliation.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anders Heissel | 18/09
2 kommentarer
af Alice Kunkel | 17/09
7 kommentarer
af Jørn Rosborg | 17/09
1 Kommentar
af Peter Christian Gøtzsche | 17/09
1 Kommentar
af Jens Ole Mathiesen | 16/09
3 kommentarer
af Annette Randløv | 16/09
2 kommentarer
af Jens Ole Mathiesen | 15/09
4 kommentarer
af Jens Ole Mathiesen | 14/09
4 kommentarer
af Steffen Thirstrup | 11/09
4 kommentarer
af Jane Skjøth-Rasmussen | 11/09
8 kommentarer